Scholarlink

<p>Breast cancer represents the most common malignancy in women and, in the majority of cases, is treated with curative intent. Following completion of primary therapy, patients transition to follow-up care. Structured surveillance has been established by the German S3 guideline and the Gynecologic Oncology Working Group (AGO), Breast Committee. Follow-up care comprises a&#xa0;clinical examination including medical history assessment and breast imaging diagnostics. In cases of hereditary breast cancer, imaging surveillance may be performed at shorter intervals and with greater intensity at Centers for Familial Breast and Ovarian Cancer (FBREK). The objectives of follow-up care include the early detection of locoregional recurrences, contralateral breast cancer, symptomatic distant disease and treatment-related adverse effects. Risk-adapted modification of follow-up care based on, for instance, the detection of circulating tumor cells (CTCs) or circulating tumor-associated DNA (ctDNA) is currently the focus of ongoing research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nachsorge Mammakarzinom – Was ist Standard – und warum nicht mehr?

  • 期刊论文

  • 发表日期：

    2026年1月12日

查看全文
  • Katharina Kaschner,
  • Meike Baur,
  • Anna Claussen,
  • Annika Hielbig,
  • Nikolas Tauber,
  • Achim Rody,
  • Maggie Banys-Paluchowski

摘要

Breast cancer represents the most common malignancy in women and, in the majority of cases, is treated with curative intent. Following completion of primary therapy, patients transition to follow-up care. Structured surveillance has been established by the German S3 guideline and the Gynecologic Oncology Working Group (AGO), Breast Committee. Follow-up care comprises a clinical examination including medical history assessment and breast imaging diagnostics. In cases of hereditary breast cancer, imaging surveillance may be performed at shorter intervals and with greater intensity at Centers for Familial Breast and Ovarian Cancer (FBREK). The objectives of follow-up care include the early detection of locoregional recurrences, contralateral breast cancer, symptomatic distant disease and treatment-related adverse effects. Risk-adapted modification of follow-up care based on, for instance, the detection of circulating tumor cells (CTCs) or circulating tumor-associated DNA (ctDNA) is currently the focus of ongoing research.